San Francisco, CA (March 6, 2019) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2018 and provided updates on its programs. For the fourth quarter 2018, KindredBio reported net product revenues of $1.3 […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2019-03-06 16:02:432019-03-06 16:03:27Kindred Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, March 6, 2019 San Francisco, CA (February 19, 2019) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth […]
SAN FRANCISCO, February 13, 2019 — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch (BAML) Animal Health Summit on February 25 in New York City and at the Barclays Global Healthcare Conference on March 12 in Miami. During this […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2019-02-13 08:33:462019-02-13 08:33:47Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference
SAN FRANCISCO, California. (January 23, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced that it has closed its public offering of 4,847,250 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 632,250 additional […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2019-01-23 16:13:532019-01-23 16:13:53Kindred Biosciences Announces Closing of Public Offering of Common Stock and the Full Exercise of Underwriters’ Option to Purchase Additional Shares
San Francisco, CA. (January 22, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has been named Best Company in North America by Animal Pharm, a leading industry publication. In announcing the honor, Animal Pharm noted KindredBio’s transition to a […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2019-01-22 08:31:592019-01-22 08:31:59Kindred Biosciences Named Best Company in North America by Leading Industry Publication
0.06 (0.69%)
Kindred Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, CA (March 6, 2019) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2018 and provided updates on its programs. For the fourth quarter 2018, KindredBio reported net product revenues of $1.3 […]
Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results
/in Frontpage, Investor, News /by Katja BuhrerCompany to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, March 6, 2019 San Francisco, CA (February 19, 2019) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth […]
Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference
/in Frontpage, Investor, News /by Katja BuhrerSAN FRANCISCO, February 13, 2019 — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch (BAML) Animal Health Summit on February 25 in New York City and at the Barclays Global Healthcare Conference on March 12 in Miami. During this […]
Kindred Biosciences Announces Closing of Public Offering of Common Stock and the Full Exercise of Underwriters’ Option to Purchase Additional Shares
/in Frontpage, Investor, News /by Katja BuhrerSAN FRANCISCO, California. (January 23, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced that it has closed its public offering of 4,847,250 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 632,250 additional […]
Kindred Biosciences Named Best Company in North America by Leading Industry Publication
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, CA. (January 22, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has been named Best Company in North America by Animal Pharm, a leading industry publication. In announcing the honor, Animal Pharm noted KindredBio’s transition to a […]